$ALLR
Allarity Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000121390024065252 Filed on August 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.589M $2.313M
YoY Change -35.93% -24.19%
% of Gross Profit
Research & Development $1.021M $1.058M
YoY Change -47.59% -4.25%
% of Gross Profit
Depreciation & Amortization $5.000K $1.000K
YoY Change -50.0% -88.89%
% of Gross Profit
Operating Expenses $12.31M $3.371M
YoY Change 178.2% -18.89%
Operating Profit -$12.31M -$3.371M
YoY Change 178.2% -18.89%
Interest Expense $346.0K $1.742M
YoY Change 917.65% 1126.76%
% of Operating Profit
Other Income/Expense, Net $346.0K $1.742M
YoY Change -1747.62% -1.91%
Pretax Income -$11.97M -$1.629M
YoY Change 168.92% -31.55%
Income Tax -$377.0K
% Of Pretax Income
Net Earnings -$11.59M -$1.629M
YoY Change 160.63% -31.55%
Net Earnings / Revenue
Basic Earnings Per Share -$7.71 -$0.11
Diluted Earnings Per Share -$7.71 -$0.11
COMMON SHARES
Basic Shares Outstanding 42.38M shares 17.61M shares
Diluted Shares Outstanding 14.98M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $18.50M $19.23M
Short-Term Investments
Other Short-Term Assets $100.0K $131.0K
YoY Change -90.28% -91.24%
Inventory
Prepaid Expenses $151.0K $366.0K
Receivables
Other Receivables
Total Short-Term Assets $20.37M $21.31M
YoY Change 364.24% 478.11%
LONG-TERM ASSETS
Property, Plant & Equipment $12.00K $17.00K
YoY Change -58.62% -34.62%
Goodwill
YoY Change
Intangibles $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $12.00K $9.574M
YoY Change -99.87% -1.7%
TOTAL ASSETS
Total Short-Term Assets $20.37M $21.31M
Total Long-Term Assets $12.00K $9.574M
Total Assets $20.38M $30.88M
YoY Change 46.87% 130.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.693M $7.753M
YoY Change -26.06% -4.15%
Accrued Expenses $1.322M $1.465M
YoY Change -10.98% -23.74%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.414M $10.62M
YoY Change -52.91% -16.2%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.414M $10.62M
Total Long-Term Liabilities
Total Liabilities $7.414M $11.05M
YoY Change -57.03% -21.92%
SHAREHOLDERS EQUITY
Retained Earnings -$111.5M -$99.90M
YoY Change 20.24% 13.16%
Common Stock $0.00 $3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.96M $19.84M
YoY Change
Total Liabilities & Shareholders Equity $20.38M $30.88M
YoY Change 46.87% 130.02%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$11.59M -$1.629M
YoY Change 160.63% -31.55%
Depreciation, Depletion And Amortization $5.000K $1.000K
YoY Change -50.0% -88.89%
Cash From Operating Activities -$5.443M -$7.216M
YoY Change 1.36% 189.1%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.868M 26.31M
YoY Change -24.53% 818.29%
NET CHANGE
Cash From Operating Activities -5.443M -7.216M
Cash From Investing Activities
Cash From Financing Activities 4.868M 26.31M
Net Change In Cash -575.0K 19.09M
YoY Change -153.24% 5074.25%
FREE CASH FLOW
Cash From Operating Activities -$5.443M -$7.216M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1336.40
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q2 allr Gain On Extinguishment Of Series A Convertible Preferred Stock
GainOnExtinguishmentOfSeriesAConvertiblePreferredStock
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41160
dei Entity Registrant Name
EntityRegistrantName
ALLARITY THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-2147982
dei Entity Address Address Line1
EntityAddressAddressLine1
24 School Street
dei Entity Address Address Line2
EntityAddressAddressLine2
2nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02108
dei City Area Code
CityAreaCode
(401)
dei Local Phone Number
LocalPhoneNumber
426-4664
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ALLR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42379508 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19233000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
166000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
131000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
209000 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
366000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
781000 usd
CY2024Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
1579000 usd
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
815000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
21309000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1971000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20000 usd
CY2024Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
9557000 usd
CY2023Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
9871000 usd
CY2024Q2 us-gaap Assets
Assets
30883000 usd
CY2023Q4 us-gaap Assets
Assets
11862000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7753000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8416000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1465000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1309000 usd
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
16000 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3083000 usd
CY2024Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
57000 usd
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
59000 usd
CY2024Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1325000 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1300000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10616000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14167000 usd
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
432000 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
446000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
11048000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
14613000 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
1742000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35039196 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35039196 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
294347 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
294347 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
120285000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
90369000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-530000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-411000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99923000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94451000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
19835000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2751000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30883000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11862000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1058000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1105000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3228000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2532000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2313000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3051000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4383000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5292000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
3371000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4156000 usd
us-gaap Operating Expenses
OperatingExpenses
7611000 usd
us-gaap Operating Expenses
OperatingExpenses
7824000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3371000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4156000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7611000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7824000 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
53000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
53000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
7000 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
426000 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
142000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
528000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
234000 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-128000 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-26000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-52000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
69000 usd
CY2024Q2 allr Change In Fair Value Adjustment Of Warrant Derivative Liabilities
ChangeInFairValueAdjustmentOfWarrantDerivativeLiabilities
-2243000 usd
CY2023Q2 allr Change In Fair Value Adjustment Of Warrant Derivative Liabilities
ChangeInFairValueAdjustmentOfWarrantDerivativeLiabilities
-1941000 usd
allr Change In Fair Value Adjustment Of Warrant Derivative Liabilities
ChangeInFairValueAdjustmentOfWarrantDerivativeLiabilities
-2662000 usd
allr Change In Fair Value Adjustment Of Warrant Derivative Liabilities
ChangeInFairValueAdjustmentOfWarrantDerivativeLiabilities
-2250000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1742000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1776000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2135000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2092000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1629000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2380000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5476000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5732000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1629000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2380000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5472000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5732000 usd
CY2024Q2 us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
71000 usd
CY2023Q2 us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
7287000 usd
us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
299000 usd
us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
7287000 usd
CY2024Q2 allr Gain On Extinguishment Of Series A Convertible Preferred Stock
GainOnExtinguishmentOfSeriesAConvertiblePreferredStock
31000 usd
allr Gain On Extinguishment Of Series A Convertible Preferred Stock
GainOnExtinguishmentOfSeriesAConvertiblePreferredStock
222000 usd
CY2024Q2 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.05 pure
CY2023Q2 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.05 pure
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.05 pure
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.05 pure
CY2023Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
119000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
123000 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1669000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9786000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5549000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13142000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-525.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1336.4
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14979095 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18621 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7641826 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9834 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1629000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2380000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5472000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5732000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-144000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-29000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-119000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
55000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1773000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2409000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5591000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5677000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-113000 usd
CY2023Q1 allr Deemed Dividend Percentage
DeemedDividendPercentage
0.05 pure
CY2023Q1 allr Deemed Dividend Convertible Preferred Stock To Redemption Value
DeemedDividendConvertiblePreferredStockToRedemptionValue
-167000 usd
CY2023Q1 allr Roundcommonsharesissued
Roundcommonsharesissued
1-for-35
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-40
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
565000 usd
CY2023Q1 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
2000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
-121000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
84000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3352000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-3102000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
6815000 usd
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-40
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3772000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
812000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
119000 usd
CY2023Q2 allr Eliminations Of Series A Redemption Rights
EliminationsOfSeriesARedemptionRights
624000 usd
CY2023Q2 allr Stock Issued During Period Value Issuance Of Series A Preferred Stock As Repayment Of Debt
StockIssuedDuringPeriodValueIssuanceOfSeriesAPreferredStockAsRepaymentOfDebt
453000 usd
CY2023Q2 allr Redemption Of Series A Preferred Stock Amount
RedemptionOfSeriesAPreferredStockAmount
-1652000 usd
CY2023Q2 allr Exchange Of Series C Preferred Stock For Series A Preferred Stock Amount
ExchangeOfSeriesCPreferredStockForSeriesAPreferredStockAmount
1447000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
180000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-29000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2380000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-723000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2751000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
90000 usd
CY2024Q1 allr Stock Issued During Period Value Sale Of Common Shares Net
StockIssuedDuringPeriodValueSaleOfCommonSharesNet
40000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
-32000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
25000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3843000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-6471000 usd
CY2024Q2 allr Stock Issued During Period Value Cashless Exercise Of Exchange Warrants
StockIssuedDuringPeriodValueCashlessExerciseOfExchangeWarrants
405000 usd
CY2024Q2 allr Stock Issued During Period Value Sale Of Common Shares Net
StockIssuedDuringPeriodValueSaleOfCommonSharesNet
27652000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
22000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-144000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1629000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
19835000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5472000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5732000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
19000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
-10000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
59000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-23000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
59000 usd
us-gaap Noncash Contribution Expense
NoncashContributionExpense
376000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
116000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
200000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2662000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2250000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-14000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-78000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
26000 usd
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
764000 usd
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
762000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-415000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-371000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-573000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1838000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
159000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
282000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-2000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-5000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-8000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8703000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5697000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
27689000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
6815000 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
1160000 usd
allr Payment To Repurchase Of Series B Preferred Stock
PaymentToRepurchaseOfSeriesBPreferredStock
2000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1340000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1050000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1340000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3348000 usd
us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
1652000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27689000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4023000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
18986000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1674000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
166000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2029000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19233000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
420000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
6000 usd
us-gaap Interest Paid Net
InterestPaidNet
408000 usd
us-gaap Interest Paid Net
InterestPaidNet
79000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1819000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
3334000 usd
allr Deemed Dividend On Series A Preferred Stock
DeemedDividendOnSeriesAPreferredStock
-299000 usd
allr Deemed Dividend On Series A Preferred Stock
DeemedDividendOnSeriesAPreferredStock
-207000 usd
allr Gain Loss On Extinguishment Of Series A Preferred Stock
GainLossOnExtinguishmentOfSeriesAPreferredStock
222000 usd
us-gaap Stock Issued1
StockIssued1
90000 usd
allr Stock Issued During Period Shares Cashless Exercise Of3i Exchange Warrants
StockIssuedDuringPeriodSharesCashlessExerciseOf3iExchangeWarrants
2359650 shares
allr Stock Issued During Period Shares Cashless Exercise Of3i Exchange Warrants
StockIssuedDuringPeriodSharesCashlessExerciseOf3iExchangeWarrants
2359650 shares
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
3632366 shares
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
3632366 shares
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
405000 usd
allr Issuance Of Series A Preferred Stock
IssuanceOfSeriesAPreferredStock
5577 shares
allr Issuance Of Series A Preferred Stock
IssuanceOfSeriesAPreferredStock
5577 shares
allr Stock Issued During Period Shares Exchange Of Series C Preferred Stock For Series A Preferred Stock Shares
StockIssuedDuringPeriodSharesExchangeOfSeriesCPreferredStockForSeriesAPreferredStockShares
5199 shares
allr Issuance Of Promissory Note
IssuanceOfPromissoryNote
350000 usd
allr Issuance Of Promissory Note
IssuanceOfPromissoryNote
350000 usd
allr Issuance Of Series A Preferred Stock To Extinguish Promissory Note
IssuanceOfSeriesAPreferredStockToExtinguishPromissoryNote
453000 usd
allr Deemed Dividend On Elimination Of Series A Redemption Rights
DeemedDividendOnEliminationOfSeriesARedemptionRights
-3328000 usd
allr Deemed Dividend On Exchange Of Series C Preferred Stock For Series A Preferred Stock
DeemedDividendOnExchangeOfSeriesCPreferredStockForSeriesAPreferredStock
-3752000 usd
allr Reclassification Of Derivative Liabilities Related To Converted Preferred Stock
ReclassificationOfDerivativeLiabilitiesRelatedToConvertedPreferredStock
-123000 usd
CY2024Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
the Company effected a 1-for-20 reverse stock split of the shares of its Common Stock
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99900000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19200000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
-144000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
-29000 usd
us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
119000 usd
us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
55000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>(c) Concentrations of credit risk and of significant suppliers</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents in financial institutions in amounts that could exceed government-insured limits. The Company does not believe it is subject to additional credit risks beyond those normally associated with commercial banking relationships. The Company has not experienced losses on its cash and cash equivalents accounts and management believes, based upon the quality of the financial institutions, that the credit risk regarding these deposits is not significant. The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply its requirements for supplies and raw materials related to these programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</span></p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> <i>(g) Reclassification</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During the six months ended June 30, 2023, we have reclassified financing costs of $9 from other income and expenses to general and administrative expenses with no net impact upon our operating results or cash flows for either the current or prior periods. </span></p>
CY2024Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
9557000 usd
CY2023Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
9871000 usd
CY2024Q2 allr Accrued Development Cost Liability
AccruedDevelopmentCostLiability
214000 usd
CY2023Q4 allr Accrued Development Cost Liability
AccruedDevelopmentCostLiability
114000 usd
CY2024Q2 allr Accruedinteresttonmilestoneliabilities
Accruedinteresttonmilestoneliabilities
192000 usd
CY2023Q4 allr Accruedinteresttonmilestoneliabilities
Accruedinteresttonmilestoneliabilities
101000 usd
CY2024Q2 allr Accrued Audit And Legal
AccruedAuditAndLegal
660000 usd
CY2023Q4 allr Accrued Audit And Legal
AccruedAuditAndLegal
425000 usd
CY2024Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
298000 usd
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
398000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
150000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
101000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
121000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1465000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1309000 usd
CY2024Q1 us-gaap Accounts Payable Interest Bearing Interest Rate
AccountsPayableInterestBearingInterestRate
0.05 pure
CY2024Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1325000 usd
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
440000 usd
CY2024Q1 allr Debt Instruments Aggregate Purchase Price
DebtInstrumentsAggregatePurchasePrice
400000 usd
CY2024Q1 allr Discount Rate
DiscountRate
0.10 pure
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
440000 usd
CY2024Q1 allr Debt Instruments Aggregate Purchase Price
DebtInstrumentsAggregatePurchasePrice
400000 usd
CY2024Q1 allr Discount Rate
DiscountRate
0.10 pure
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
660000 usd
CY2024Q1 allr Debt Instruments Aggregate Purchase Price
DebtInstrumentsAggregatePurchasePrice
600000 usd
CY2024Q1 allr Discount Rate
DiscountRate
0.10 pure
CY2024Q2 allr Gross Proceeds Percentage
GrossProceedsPercentage
1 pure
allr Percentage Of Proceeds To Redeem
PercentageOfProceedsToRedeem
0.20 pure
CY2024Q1 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
5000000 usd
CY2024Q1 us-gaap Financing Receivable Percent Past Due1
FinancingReceivablePercentPastDue1
0.35 pure
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
34000 usd
us-gaap Interest Expense Other
InterestExpenseOther
43000 usd
us-gaap Contractual Interest Expense On Prepetition Liabilities Not Recognized In Statement Of Operations
ContractualInterestExpenseOnPrepetitionLiabilitiesNotRecognizedInStatementOfOperations
33000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10000 usd
CY2024Q1 us-gaap Preferred Units Outstanding
PreferredUnitsOutstanding
1417 shares
CY2024Q1 us-gaap Other Cash Equivalents At Carrying Value
OtherCashEquivalentsAtCarryingValue
1742000 usd
CY2024Q1 us-gaap Investment Income Dividend
InvestmentIncomeDividend
228000 usd
CY2024Q1 allr Revised Price Per Share
RevisedPricePerShare
8.95
CY2024Q1 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
170952 shares
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
122000 usd
CY2024Q1 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
7
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
69000 usd
CY2024Q1 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
1215 shares
CY2024Q2 us-gaap Preferred Units Issued
PreferredUnitsIssued
0 shares
CY2024Q2 us-gaap Preferred Units Outstanding
PreferredUnitsOutstanding
0 shares
allr Stock Issued During Period Shares Cashless Exercise Of3i Exchange Warrants
StockIssuedDuringPeriodSharesCashlessExerciseOf3iExchangeWarrants
2359650 shares
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
405000 usd
allr Preferred Stock Shares Exercised
PreferredStockSharesExercised
12052 shares
CY2023Q1 us-gaap Payments For Proceeds From Previous Acquisition
PaymentsForProceedsFromPreviousAcquisition
1200000 usd
CY2023Q2 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
1200000 usd
CY2023Q2 allr Debt Discount Opening
DebtDiscountOpening
40000 usd
CY2023Q2 us-gaap Redemption Premium
RedemptionPremium
1485000 usd
allr Percentage Of Accrue Dividends
PercentageOfAccrueDividends
0.05 pure
CY2023Q2 allr Timing Of Liquidity Event
TimingOfLiquidityEvent
Q3 - 2023
CY2024Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.0001
CY2024Q2 us-gaap Common Unit Authorized
CommonUnitAuthorized
750500000 shares
CY2024Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
30000000 usd
CY2024Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27652000 usd
CY2024Q2 us-gaap Prepayment Fees On Advances Net
PrepaymentFeesOnAdvancesNet
855000 usd
CY2024Q2 us-gaap Redeemable Noncontrolling Interest Equity Common Fair Value
RedeemableNoncontrollingInterestEquityCommonFairValue
1510000 usd
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
600000
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
7500000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27692000 usd
CY2023Q2 us-gaap Common Unit Issued
CommonUnitIssued
241893 shares
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3899000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
108416 shares
allr Percentage Of Difference Between Issued And Outstanding Shares
PercentageOfDifferenceBetweenIssuedAndOutstandingShares
0.15 pure
allr Recapitalization Exchange Of Shares
RecapitalizationExchangeOfShares
108416 shares
CY2022Q4 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.05 pure
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-22000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
180000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
59000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
157520
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y1M28D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
8 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
186504
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
104354
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y7M2D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
11 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
27524
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y6M18D
CY2024Q1 allr Interest Payable
InterestPayable
0.05 pure
CY2024Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
3600000 usd
CY2024Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1325000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
192000 usd
CY2023Q3 us-gaap Capital Units
CapitalUnits
100000 usd
CY2024Q1 us-gaap Capital Units
CapitalUnits
850000 usd
CY2024Q2 us-gaap Other Additional Capital
OtherAdditionalCapital
150000 usd
allr Sales Milestone Payment
SalesMilestonePayment
50000000 usd
allr Licensed Product Sales
LicensedProductSales
1000000000 usd
CY2024Q2 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
100000 usd
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
256678 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
69092 shares
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
allr Gain On Extinguishment Of Series A Convertible Preferred Stock
GainOnExtinguishmentOfSeriesAConvertiblePreferredStock
usd
CY2024Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-525.53
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14979095 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7641826 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18621 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9834 shares
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2023Q1 allr Stock Issued During Period Value Round Up Of Common Shares Issued As A Resulteverse Stock Splits
StockIssuedDuringPeriodValueRoundUpOfCommonSharesIssuedAsAResulteverseStockSplits
usd
CY2023Q2 allr Stock Issued During Period Value Round Up Of Common Shares Issued As A Resulteverse Stock Splits
StockIssuedDuringPeriodValueRoundUpOfCommonSharesIssuedAsAResulteverseStockSplits
usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2024Q1 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
usd
CY2024Q1 allr Deemed Dividend On Modificationof Preferred Shares
DeemedDividendOnModificationofPreferredShares
usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2024Q2 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
usd
CY2024Q2 allr Deemed Dividend On Modificationof Preferred Shares
DeemedDividendOnModificationofPreferredShares
usd
us-gaap Noncash Contribution Expense
NoncashContributionExpense
usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
allr Payment To Repurchase Of Series B Preferred Stock
PaymentToRepurchaseOfSeriesBPreferredStock
usd
us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
allr Gain Loss On Extinguishment Of Series A Preferred Stock
GainLossOnExtinguishmentOfSeriesAPreferredStock
usd
us-gaap Stock Issued1
StockIssued1
usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
usd
allr Stock Issued During Period Shares Exchange Of Series C Preferred Stock For Series A Preferred Stock Shares
StockIssuedDuringPeriodSharesExchangeOfSeriesCPreferredStockForSeriesAPreferredStockShares
shares
allr Issuance Of Series A Preferred Stock To Extinguish Promissory Note
IssuanceOfSeriesAPreferredStockToExtinguishPromissoryNote
usd
allr Deemed Dividend On Elimination Of Series A Redemption Rights
DeemedDividendOnEliminationOfSeriesARedemptionRights
usd
allr Deemed Dividend On Exchange Of Series C Preferred Stock For Series A Preferred Stock
DeemedDividendOnExchangeOfSeriesCPreferredStockForSeriesAPreferredStock
usd
allr Reclassification Of Derivative Liabilities Related To Converted Preferred Stock
ReclassificationOfDerivativeLiabilitiesRelatedToConvertedPreferredStock
usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001860657

Files In Submission

Name View Source Status
0001213900-24-065252-index-headers.html Edgar Link pending
0001213900-24-065252-index.html Edgar Link pending
0001213900-24-065252.txt Edgar Link pending
0001213900-24-065252-xbrl.zip Edgar Link pending
allr-20240630.xsd Edgar Link pending
ea0210398-10q_allarity.htm Edgar Link pending
ea021039801ex31-1_allarity.htm Edgar Link pending
ea021039801ex31-2_allarity.htm Edgar Link pending
ea021039801ex32-1_allarity.htm Edgar Link pending
ea021039801ex32-2_allarity.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
ea0210398-10q_allarity_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
allr-20240630_cal.xml Edgar Link unprocessable
allr-20240630_def.xml Edgar Link unprocessable
allr-20240630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
allr-20240630_pre.xml Edgar Link unprocessable